信達國際控股(00111.HK):全年總收入1.42億港元 同比下跌42%
格隆匯3月13日丨信達國際控股(00111.HK)發佈公吿,截至2022年12月31日止年度,全年總收入1.42億港元,較去年下跌42%,其中,營業收益為1.36億港元,較去年下跌34%。其他收入為2972萬港元,較去年下跌49%。其他虧損淨額為2397萬港元(2021年:1949萬港元),較去年上升23%。開支方面,集團着力控制成本,人員費用大幅下跌,同比下跌36%;加上其他營運支出有所減少,因此經營成本(不包括佣金開支及財務費用)為1.28億港元(2021年:1.79億港元),較去年下跌28%。而財務費用較去年上升7%,主要原因是市場利率上升抵銷整體借款規模下跌的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.